Your browser doesn't support javascript.
Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
Hasan, Syed Shahzad; Kow, Chia Siang; Bain, Amie; Kavanagh, Sallianne; Merchant, Hamid A; Hadi, Muhammad Abdul.
  • Hasan SS; Department of Pharmacy, University of Huddersfield , Huddersfield, UK.
  • Kow CS; School of Postgraduate Studies, International Medical University , Kuala Lumpur, Malaysia.
  • Bain A; Department of Pharmacy, University of Huddersfield , Huddersfield, UK.
  • Kavanagh S; Department of Pharmacy, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, UK.
  • Merchant HA; Department of Pharmacy, University of Huddersfield , Huddersfield, UK.
  • Hadi MA; Department of Pharmacy, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield, UK.
Expert Opin Pharmacother ; 22(2): 229-240, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-861954
ABSTRACT

INTRODUCTION:

Diabetes mellitus is one of the most prevalent comorbidities identified in patients with coronavirus disease 2019 (COVID-19). This article aims to discuss the pharmacotherapeutic considerations for the management of diabetes in hospitalized patients with COVID-19. AREAS COVERED We discussed various aspects of pharmacotherapeutic management in hospitalized patients with COVID-19 (i) susceptibility and severity of COVID-19 among individuals with diabetes, (ii) glycemic goals for hospitalized patients with COVID-19 and concurrent diabetes, (iii) pharmacological treatment considerations for hospitalized patients with COVID-19 and concurrent diabetes. EXPERT OPINION The glycemic goals in patients with COVID-19 and concurrent type 1 (T1DM) or type 2 diabetes (T2DM) are to avoid disruption of stable metabolic state, maintain optimal glycemic control, and prevent adverse glycemic events. Patients with T1DM require insulin therapy at all times to prevent ketosis. The management strategies for patients with T2DM include temporary discontinuation of certain oral antidiabetic agents and consideration for insulin therapy. Patients with T2DM who are relatively stable and able to eat regularly may continue with oral antidiabetic agents if glycemic control is satisfactory. Hyperglycemia may develop in patients with systemic corticosteroid treatment and should be managed upon accordingly.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents / Insulin Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Expert Opin Pharmacother Journal subject: Pharmacology Year: 2021 Document Type: Article Affiliation country: 14656566.2020.1837114

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents / Insulin Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Expert Opin Pharmacother Journal subject: Pharmacology Year: 2021 Document Type: Article Affiliation country: 14656566.2020.1837114